Pembrolizumab for melanoma- safety profile and future trends

Expert Opinion on Drug Safety

Volumn 15, Issue 6, 2016, Pages 727-729

  Daud, Adil ^a   Nandoskar, Prachi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer immunotherapy; Melanoma; PD 1; pembrolizumab; safety

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

COLITIS; DECREASED APPETITE; DIARRHEA; DRUG APPROVAL; DRUG SAFETY; EDITORIAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPIGMENTATION; HYPOTHYROIDISM; MELANOMA; NAUSEA; NEPHRITIS; PAPULAR RASH; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; RASH; RISK ASSESSMENT; TREATMENT INTERRUPTION; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 84975311519     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1175430     Document Type: Editorial

References (14)

1. S.L.Topalian, C.G.Drake, D.M.Pardoll Immune check- point blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461.
2. D.M.Pardoll. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;13:1129–1132.
3. M.A.Postow, M.F.Callahan, J.D.Wolchok. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
4. D.B.Johnson, C.Peng, J.A.Sosman. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97–106.
5. A.Daud, A.Ribas, C.Robert, et al. Long-term efficacy of pembrolizumab in a pooled analysis of 655 patients with advanced melanoma enrolled in KEYNOTE-001 [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:9005.
6. C.Robert, A.Ribas, J.D.Wolchok, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.•• Important findings from KEYNOTE-001 trial.
7. A.Patnaik, S.P.Kang, D.Rasco, et al. Phase I study of pembrolizumab (MK-3475;anti–PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293.•• Important findings from KEYNOTE-001 trial.
8. A.Ribas, I.Puzanov, R.Dummer, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet. 2015;16:908–918.•• Important findings from KEYNOTE-002 trial.
9. I.Puzanov, R.Dummer, J.Schachter, et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (MK-3475) versus chemotherapy in patients with ipilimumab- refractory advanced melanoma [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:3012.
10. A.Daud. Current and emerging perspectives on immunotherapy for melanoma. Semin Oncol. 2015;42(Suppl 3):S3–S11.• Comprehensive summary of current trends in immunotherapy for melanoma.
11. C.Robert, J.Schachter, G.V.Long, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.•• Important findings from KEYNOTE-006 trial.
12. C.Robert, L.Min, A.M.Joshua, et al. Immune-related thyroid disorders with pembrolizumab (MK-3475) in patients with advanced melanoma treated in KEYNOTE-001 [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:9050.
13. M.Sanlorenzo, D.A.Vujic, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–1212.
14. J.D.Wolchok, A.Hoos, S.O’Day, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.